Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Oct 07, 16:00
Pharma Mar Gross Profit Margin (Quarterly) : 86.21% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.21% |
| March 31, 2026 | 86.61% |
| December 31, 2025 | 93.59% |
| September 30, 2025 | 87.90% |
| June 30, 2025 | 95.07% |
| March 31, 2025 | 91.25% |
| December 31, 2024 | 92.88% |
| September 30, 2024 | 95.60% |
| June 30, 2024 | 92.78% |
| March 31, 2024 | 95.35% |
| December 31, 2023 | 93.95% |
| September 30, 2023 | 91.60% |
| June 30, 2023 | 95.91% |
| March 31, 2023 | 93.73% |
| December 31, 2022 | 88.66% |
| June 30, 2022 | 92.45% |
| March 31, 2022 | 92.88% |
| December 31, 2021 | 91.88% |
| September 30, 2021 | 91.98% |
| June 30, 2021 | 96.44% |
| March 31, 2021 | 88.43% |
| December 31, 2020 | 90.65% |
| September 30, 2020 | 89.83% |
| June 30, 2020 | 94.35% |
| March 31, 2020 | 97.93% |
| Date | Value |
|---|---|
| December 31, 2019 | 88.14% |
| September 30, 2019 | 86.86% |
| June 30, 2019 | 87.40% |
| March 31, 2019 | 86.56% |
| December 31, 2018 | 92.57% |
| September 30, 2018 | 94.63% |
| June 30, 2018 | 92.71% |
| March 31, 2018 | 90.62% |
| December 31, 2017 | 83.76% |
| September 30, 2017 | 73.31% |
| June 30, 2017 | 71.03% |
| March 31, 2017 | 75.49% |
| December 31, 2016 | 81.42% |
| September 30, 2016 | 74.91% |
| June 30, 2016 | 72.12% |
| March 31, 2016 | 75.22% |
| December 31, 2015 | 86.03% |
| September 30, 2015 | 70.44% |
| June 30, 2015 | 68.81% |
| March 31, 2015 | 76.01% |
| December 31, 2014 | 75.80% |
| September 30, 2014 | 70.37% |
| June 30, 2014 | 69.91% |
| March 31, 2014 | 76.22% |
| December 31, 2013 | 77.06% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Oryzon Genomics SA | -- |
| Grifols SA | 37.57% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alkermes Plc | 75.30% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 24.39% |
| Return on Assets | 15.06% |
| Return on Invested Capital | 20.12% |
| Profit Margin (Quarterly) | -1.96% |
| Operating Margin (Quarterly) | -4.23% |
| Return on Net Operating Assets | 35.07% |